Chronic myelogenous leukemia

In Ph+BCR-ABL1P210+ acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166–78.

  2. 2.

    Ravandi F, Kebriaei P. Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 2009;23:1043. vi

  3. 3.

    Chiaretti S, Vitale A, Cazzaniga G, Orlando SM, Silvestri D, Fazi P, et al. Clinico-biologic features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts. Haematologica. 2013;98:1702–10.

  4. 4.

    Burmeister T, Schwartz S, Bartram CR, Gokbuget N, Hoelzer D, Thiel S. Patients’ age and BCR-ABL frequency in adult B-cell precursor ALL: a retrospective analysis from the GMALL study group. Blood. 2008;112:918–9.

  5. 5.

    Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood. 1996;88:2375–84.

  6. 6.

    Chereda B, Melo JV. The biology and pathogenesis of chronic myeloid leukemia. In: Hehlmann R, editor. Chronic myeloid leukemia. Switzerland: Springer International Publishing; 2016. p. 17–40.

  7. 7.

    Ravandi F, O’Brien S, Cortes JE, Thomas DM, Garris R, Faderl S, et al. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015;121:4158–64.

  8. 8.

    Baccarani M, Castagnetti F, Gugliotta G, Rosti G, Soverini S, Albeer A, et al. The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. an international overview. Leukemia. 2019. https://doi.org/10.1038/s41375-018-0341-4.

  9. 9.

    Hai A, Kizilbash NA, Zaidi SH, Alruwaili J, Shahzad K. Differences in structural elements of Bcr-Abl oncoprotein isoforms in chronic myelogenous leukemia. Bioinformation. 2014;10:108–14.

  10. 10.

    Vignetti M, Fazi P, Cimino G, Martinelli G, Di Raimomdo F, Ferrara F, et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell’ Adulto (GIMEMA) LAL0201-B protocol. Blood. 2007;109:3676–8.

  11. 11.

    Foà R, Vitale A, Vignetti M, Meloni G, Guarini A, De Propris MS, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011;118:6521–8.

  12. 12.

    Malagola M, Papayannidis C, Baccarani M. Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives. Ann Hematol. 2016;95:681–93.

  13. 13.

    Score J, Calasanz MJ, Ottman O, Pane F, Yeh RF, Sobrinho-Simoes MA, et al. Analysis of genomic breakpoints in p190 and p210 BCR-ABL indicate distinct mechanisms of formation. Leukemia. 2010;24:1742–50.

  14. 14.

    Reckel S, Hamelin R, Georgeon S, Armand F, Jolliet Q, Chiappe D, et al. Differences in structural elements of bcr-Abl oncoprotein isoforms in chronic myelogenous leukemia. Leukemia. 2017;31:1502–15.

  15. 15.

    Cutler J, Tahir R, Sreenivasamurthy SK, Mitchell C, Renuse S, Nirujogi RS. Differential signaling through p190 and p210 BCR-ABL fusion proteins reveales by interactome and phosphoproteome analysis. Leukemia. 2017;31:1513–24.

Download references

Acknowledgements

This work was supported in part by the European Leukemia Net Foundation and by AIRC 5×1000 (21198). The technical assistance of Mrs Chiara Ferri is kindly acknowledged.

Author information

Correspondence to Michele Baccarani.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Baccarani, M., Iacobucci, I., Chiaretti, S. et al. In Ph+BCR-ABL1P210+ acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent. Leukemia 34, 929–931 (2020). https://doi.org/10.1038/s41375-019-0591-9

Download citation